Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Next-Generation Therapeutics Gain Momentum
The biotechnology sector continues to advance beyond traditional drug development, with growing emphasis on innovative therapeutic platforms designed to address complex diseases through novel mechanisms of action. Across oncology, genetic medicine, RNA-based therapeutics and next-generation vaccines, companies are reporting clinical, regulatory and scientific milestones that highlight the industry's focus on developing scalable technologies capable of generating multiple treatment opportunities while improving patient outcomes.
CytoDyn Inc. (OTCQB: CYDY) is reporting the successful enrollment and initial dosing of the first participant in its Expanded Access Program (EAP) for patients with triple-negative breast cancer (TNBC). The company is advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”). The EAP is designed to provide eligible patients access to leronlimab outside of a clinical study setting. The program is intended for patients who have exhausted available treatment options and are not eligible for ongoing or planned clinical studies, in accordance with U.S. Food and Drug Administration (FDA) guidelines.
https://www.mykxlg.com/online_features/press_...4750a.html
Next-Generation Therapeutics Gain Momentum
The biotechnology sector continues to advance beyond traditional drug development, with growing emphasis on innovative therapeutic platforms designed to address complex diseases through novel mechanisms of action. Across oncology, genetic medicine, RNA-based therapeutics and next-generation vaccines, companies are reporting clinical, regulatory and scientific milestones that highlight the industry's focus on developing scalable technologies capable of generating multiple treatment opportunities while improving patient outcomes.
CytoDyn Inc. (OTCQB: CYDY) is reporting the successful enrollment and initial dosing of the first participant in its Expanded Access Program (EAP) for patients with triple-negative breast cancer (TNBC). The company is advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”). The EAP is designed to provide eligible patients access to leronlimab outside of a clinical study setting. The program is intended for patients who have exhausted available treatment options and are not eligible for ongoing or planned clinical studies, in accordance with U.S. Food and Drug Administration (FDA) guidelines.
https://www.mykxlg.com/online_features/press_...4750a.html
21
